Murray K.F.Shah U.Mohan N.Heller S.Gonz?lez-Peralta R.P.Kelly D.MEI-HWEI CHANGMieli-Vergani G.Jara P.Fujisawa T.2021-01-042021-01-0420080277-2116https://www.scopus.com/inward/record.uri?eid=2-s2.0-56049108591&doi=10.1097%2fMPG.0b013e318181b08b&partnerID=40&md5=e6707369300aa88a7d26a1b5dac54c8dhttps://scholars.lib.ntu.edu.tw/handle/123456789/537044[SDGs]SDG3adefovir; alanine aminotransferase; alpha interferon; azathioprine; budesonide; corticosteroid; cyclophosphamide; cyclosporin; hepatitis B(e) antigen; interferon; lamivudine; mercaptopurine; methotrexate; mycophenolic acid 2 morpholinoethyl ester; peginterferon; placebo; prednisone; ribavirin; tacrolimus; ursodeoxycholic acid; virus DNA; antiinflammatory agent; antivirus agent; add on therapy; alanine aminotransferase blood level; autoimmune hepatitis; chronic hepatitis; clinical trial; delta agent hepatitis; drug effect; drug half life; drug megadose; drug tolerability; hepatitis B; Hepatitis B virus; hepatitis C; Hepatitis C virus; human; immunosuppressive treatment; liver biopsy; low drug dose; patient monitoring; priority journal; review; sclerosing cholangitis; autoimmune hepatitis; child; conference paper; consensus development; differential diagnosis; mortality; practice guideline; risk factor; Anti-Inflammatory Agents; Antiviral Agents; Child; Diagnosis, Differential; Hepatitis B, Chronic; Hepatitis C, Chronic; Hepatitis, Autoimmune; Humans; Risk Factorsreview10.1097/MPG.0b013e318181b08b186648802-s2.0-56049108591